Literature DB >> 9782219

Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement.

D Manganelli1, M Pazzagli, D Mazzantini, G Punzi, M Manca, C Vignali, A Palla, R Troiani, G Rossi.   

Abstract

The aim of this study was to assess the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) until 45 days after elective total hip replacement (THR) and the efficacy of prolonged unfractioned heparin (UH) prophylaxis up to postoperative day 30. To this end 79 of 96 patients admitted consecutively to the University Hospital of Pisa for THR were randomly assigned to short- or long-term UH prophylaxis. Sixty-one patients completed the study: 28 of them received short-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 15 days) and 33 prolonged prophylaxis (subcutaneous UH 15,000 IU/24 h for 30 days). Lower limb phlebography was performed in all patients on day 45 after THR. DVT was demonstrated in 10 (16.3%) cases after hospital discharge. Among them, 2 patients also had symptomatic PE. The incidence of DVT was 21.4% in short- and 12.1% in long-term UH-treated patients. The incidence of only proximal DVT was 17.8% in short- and 3.0% in long-term UH-treated patients; although the difference was only close to significance (p = 0.085), the relative risk of developing proximal DVT was about six times greater in the former group of patients. We concluded that the risk for thromboembolism persists at least until 45 days after surgery in patients subjected to THR. Prophylaxis with UH given up to postoperative day 30 appears more effective and safer in reducing the delayed thromboembolic risk compared to prophylaxis with UH given up to discharge only.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9782219     DOI: 10.1159/000029297

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  4 in total

1.  Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.

Authors:  Jonas Lundkvist; David Bergqvist; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2007-01-16

2.  Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.

Authors:  Randall R De Martino; Adam W Beck; Matthew S Edwards; Matthew A Corriere; Jessica B Wallaert; David H Stone; Jack L Cronenwett; Philip P Goodney
Journal:  J Vasc Surg       Date:  2012-07-24       Impact factor: 4.268

3.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

4.  An obscure case of hepatic subcapsular hematoma.

Authors:  Albert Ndzengue; Fadi Hammoudeh; Pierre Brutus; Ofem Ajah; Roland Purcell; Joseph Leadon; Richard B Rafal; Simon Balmir; Danilo A Enriquez; Gerald L Posner; Eric A Jaffe; Pradeep Chandra
Journal:  Case Rep Gastroenterol       Date:  2011-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.